Psyence Biomedica…
USUSDPsyence Biomedical Ltd. (US:PBM) — Biotechnology: Pharmaceutical Preparations. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 1. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
Ettevõtte Kohta
- Veebileht
- psyencebiomed.com
- Investorite Suhted
- psyencebiomed.com/investors/
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Peakontor
- TORONTO, Canada
- Tegevjuht
- Jody Aufrichtig
- Töötajad
- 12
- Ringluses Olevad Aktsiad
- 2.29 mln seisuga 2026-03-31
- Vabalt Kaubeldavad Aktsiad
- 2.61 mln
- Turukapitalisatsioon
- 19.15 mln USD
- Siseringi Isikud
- 2.97%
- Institutsionaalsed Investorid
- 9.67%
- Tegevusala (SIC)
- Pharmaceutical Preparations
- P/E
- kahjum
- FCF
- −4.25 mln USD
- Võlg
- 10.4 mln USD
- Kasum ja FCF — 12 kuu jooksul kuni 30.09.2025 (ettevõtte viimane raport).
Kirjeldus
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
reklaam
Börsid ja Tikkerid
| Börs | Tikker | Valuuta | Hind | Tüüp |
|---|---|---|---|---|
| US USA Stocks | PBM | USD | 4.32 +4.60% | tavalised aktsiad |
Suurimad Omanikud
| Omanik | Osalus | Aktsiad | Aruande Kuupäev |
|---|---|---|---|
| AdvisorShares Trust-Advi… | 4.61% | 175 687 | 2026-08-31 |
| Parallel Advisors, LLC | 3.97% | 151 250 | 2026-06-30 |
| AdvisorShares Investment… | 3.2% | 122 184 | 2026-06-30 |
| Morgan Stanley | 0.99% | 37 804 | 2026-06-30 |
| Jane Street Group, LLC | 0.8% | 30 431 | 2026-06-30 |
| Xtx Topco Ltd | 0.4% | 15 094 | 2026-06-30 |
| Citadel Advisors Llc | 0.31% | 11 693 | 2026-06-30 |
| UBS Group AG | 0% | 60 | 2026-06-30 |
| Caitlin John, LLC | 0% | 35 | 2026-06-30 |
